Massachussets General Hospital Global Health Forum

Dr Aamir Jalal Al Mosawi talk in Massachussets General Hospital Global Health Forum

COR Annual General and Scientific Meeting – Imaging in Emergencies and Trauma:National specialist register

submitted by: biij
This is a video presentation by Zaki Morad Mohd Zaher at COR Annual General and Scientific Meeting – Imaging in Emergencies and Trauma, Kuala Lumpur (30-31 May 2009). This video is alternatively available at: http://www.biij.org/resources/2009-cor-trauma/d1am1.mp4 Other presentations at COR Annual General and Scientific Meeting – Imaging in Emergencies and Trauma is available at http://www.biij.org/biomedical-imaging-intervention-journal-resources.as... A video production of...

COR Annual General and Scientific Meeting - Imaging in Emergencies and Trauma : National specialist register

submitted by: gzonecsg
This is a video presentation by [Zaki Morad Mohd Zaher] at [COR Annual General and Scientific Meeting] ([30-31 May 2009]). This video is alternatively available at: [http://www.biij.org/resources/2009-cor-trauma/d1am1.mp4] Other presentations at [COR Annual General and Scientific Meeting – Imaging in Emergencies and Trauma] is available at http://www.biij.org/biomedical-imaging-intervention-journal-resources.as... A video production of Biomedical Imaging and Intervention Journal...

Alan Lewis: Embryonic Stem Cell Therapies for Diabetes

submitted by: CIRMTV

Embryonic stem cells have the potential to help treat 70 or more diseases, but developing those new therapies will take time. Alan Lewis is president and CEO of Novocell, a La Jolla-based company that has been developing a potential therapy for diabetes. Novocell has a CIRM grant to assemble a team of researchers who will accelerate the time it takes to get that potential therapy to the FDA for clinical trials.

Pharmacogenomic Biomarkers for Prediction of Severe Adverse Drug Reactions

submitted by: KuoOffice

Dr. Magnus Ingelman-Sundberg presents his recent paper on "Pharmacogenomic biomarkers for prediction of "severe adverse drug reactions" published in the New England Journal of Medicine on Feb 2008.

The Biology of Genomes (2008) with David Bentley Interviewed by Chris Gunter

Dr. David Bentley is Vice President and Chief Scientist at Illumina Inc, developing new DNA sequencing technology for fast, accurate sequencing of complex genomes. His major research interest is the study of human sequence variation. He was previously Head of Human Genetics and founding Member of the Board of Management at the Wellcome Trust Sanger Institute, where he played leading roles in the Institute's contribution the human genome reference sequence, The SNP Consortium and the...

Stem Cells: Biology and Promise for Regenerative Medicine: Part 2: Tapping the Potential of Adult Stem Cells (1:17:03)

submitted by: scivee-team
Stem cells have both the capacity to self-renew, that is, to divide and create additional stem cells, and also to differentiate along a specified molecular pathway. Embryonic stem cells are very nearly totipotent, reserving the elite privileges of choosing among most if not all of the differentiation pathways that specify the animal. In contrast, stem cells that reside within an adult organ or tissue have more restricted options, often able to select a differentiation program from only a few...

Imatinib (Gleevec) as a Paradigm of Targeted Cancer Therapies: Part 3: Extending the Imatinib Paradigm (22:09)

submitted by: scivee-team

The lessons learned from the clinical trials of imatinib will be reviewed in this section. This will include examples of where imatinib has or has not worked, analysis of target expression versus activation and a discussion of how the success of imatinib can be translated to other malignancies. The section concludes with what this means for research to control or cure cancer in the coming decades.

Imatinib (Gleevec) as a Paradigm of Targeted Cancer Therapies: Part 2: Imatinib Resistance and Other Diseases Targeted by Imatinib (25:12)

submitted by: scivee-team
Although the majority of patients with CML respond well to imatinib, a minority of patients have relapsed. This part of the lecture will cover what has been learned about mechanisms of relapse and how this information has been translated into new therapies for patients with imatinib resistance. Although imatinib is a relatively specific inhibitor of the ABL kinase, a couple of other kinases, KIT and the platelet derived growth factor receptor are also inhibited by imatinib. This use of this...

Adhesion, Signaling and Cancer: Part 3: Focal Adhesions as Stress Sensors (30:57)

submitted by: scivee-team
In the third segment of my seminar, I address a new frontier in cell biology, that is how cells respond to mechanical information. Cells and tissues are exposed to physical forces in vivo and excessive mechanical stress leads to a variety of pathological consequences. I describe a system for exposing cells to controlled mechanical stress and discuss the stretch response. We have discovered that the focal adhesion protein, zyxin, is exquisitely sensitive to mechanical stimulation and is...